The drug’s manufacturer issued a nationwide recall due to the possibility of adverse reactions.
Naloxone, the opioid overdose antidote has been recalled by its manufacturer Hospira for particulate matter.
The Food and Drug Administration reported that Hospira issued a voluntary nationwide recall of the drug due to "the potential presence of embedded and loose particulate matter on the syringe plunger." If a patient were to receive defective Naloxone there is a chance they could experience an adverse reaction, such as allergic reactions, pulmonary emboli, toxicity and tissue ischemia.
According to the FDA, naloxone is labeled to remind those administering the drug to inspect it for particulate matter and discoloration before giving it to an overdosing patient. Hospira has not received reports of adverse reactions.
Naloxone is available for intravenous, intramuscular and subcutaneous administration for the complete or partial reversal of an overdose of opioids. It quickly restores respiration to someone who has stopped breathing because of an overdose. Naloxone can also be used for the management of septic shock in combination with other drugs. The recall applies to single-use cartridges distributed to hospitals, wholesalers and distributors across the United States, Puerto Rico and Guam from February 2017 to February 2018.
The FDA urges anyone who experiences adverse reactions to Naloxone to immediately report it to the agency's MedWatch Adverse Event Reporting program.
Once only available in hospitals to be given by healthcare professionals, the severity of the opioid crisis has led many first responders to carry the life-saving drug. It is also available without a prescription in some areas.
Written by: By Alexa Lardieri, Staff Writer June 6, 2018, at 10:54 a.m.
On: Naloxone Recall